Multiple Myeloma Clinical Trials

A listing of 180 Multiple Myeloma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Multiple Myeloma

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 180 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

NCT06550895

Recruiting

The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: University of Iowa Hospital and Clinics, Iowa City, Iowa +11 locations

Conditions: Multiple Myeloma

Learn More ›

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781

Recruiting

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/22/2025

Locations: Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona +46 locations

Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona

City of Hope, Duarte, California

University of California San Francisco, San Francisco, California

Stanford University Medical Center, Stanford, California

Moffitt Cancer Center, Tampa, Florida

Emory University, Atlanta, Georgia

Northwestern University, Chicago, Illinois

University of Chicago, Chicago, Illinois

Indiana University, Indianapolis, Indiana

Kansas University Medical Center, Westwood, Kansas

Dana Farber Cancer Institute, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Massachusetts General Hospital, Boston, Massachusetts

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Mayo Clinic Rochester, Rochester, Minnesota

Washington University School Of Medicine, Saint Louis, Missouri

Hackensack University Medical Center, Hackensack, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Montefiore Medical Center, Bronx, New York

Roswell Park Cancer Institute, Buffalo, New York

Mount Sinai Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Levine Cancer Institute, Charlotte, North Carolina

University of Pennsylvania, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Sarah Cannon Research Institute, Nashville, Tennessee

MD Anderson Cancer Center, Houston, Texas

Froedtert Memorial, Milwaukee, Wisconsin

UZ Gent, Gent, Not set

UZ Leuven, Leuven, Not set

Peking University Third Hospital, Beijing, Not set

West China Hospital Si Chuan University, Chengdu, Not set

Fujian Medical University Union Hospital, Fuzhou, Not set

First Hospital, Zhejiang University Medical College, Hangzhou, Not set

Jiangsu Province Hospital, Nanjing, Not set

Ruijin Hospital Shanghai Jiao Tong University, Shanghai, Not set

Shanghai Fourth People s Hospital, Shanghai, Not set

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Not set

CHRU de Lille Hopital Claude Huriez, Nord, Not set

Hopital Saint Louis, Paris, Not set

Tel Aviv Sourasky Medical Center, Tel-Aviv, Not set

Nagoya City University Hospital, Nagoya, Not set

Japanese Red Cross Medical Center, Shibuya, Not set

VU Medisch Centrum, Amsterdam, Not set

University Medical Center Groningen, Groningen, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Hosp Clinico Univ de Salamanca, Salamanca, Not set

Conditions: Multiple Myeloma

Learn More ›

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

NCT06042725

Recruiting

This phase I trial tests the safety, side effects, and best dose of venetoclax in combination with lenalidomide and dexamethasone, daratumumab and dexamethasone, or daratumumab, lenalidomide, and dexamethasone in treating patients with multiple myeloma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Lenalidomide is a drug that is similar to thalidomide, and i... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/20/2025

Locations: Mayo Clinic in Rochester, Rochester, Minnesota

Conditions: Multiple Myeloma

Learn More ›

TriPRIL CAR T Cells in Multiple Myeloma

NCT05020444

Recruiting

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/19/2025

Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma

Learn More ›

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

NCT06126341

Recruiting

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

05/16/2025

Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations

Conditions: Multiple Myeloma

Learn More ›

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

NCT05199311

Recruiting

This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/16/2025

Locations: Lombardi Comprehensive Cancer Center, Washington, District of Columbia +1 locations

Conditions: Multiple Myeloma

Learn More ›

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

NCT06083922

Recruiting

The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Tufts Medical Center (Data Collection Only), Boston, Massachusetts +9 locations

Conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance

Learn More ›

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997

Recruiting

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Local Institution - 035, Hot Springs, Arkansas +278 locations

Local Institution - 035, Hot Springs, Arkansas

The Oncology Institute Of Hope And Innovation, Cerritos, California

Local Institution - 683, Corona, California

Los Angeles Cancer Network - Fountain Valley, Fountain Valley, California

USC Norris Comprehensive Cancer Center, Los Angeles, California

USC Norris Comprehensive Cancer Center, Newport, California

Yale University School Of Medicine, New Haven, Connecticut

Local Institution - 029, Fort Myers, Florida

Local Institution - 049, Jacksonville, Florida

Ocala Oncology Center, Ocala, Florida

Local Institution - 028, Saint Petersburg, Florida

BRCR Global, Tamarac, Florida

Local Institution - 034, West Palm Beach, Florida

Cleveland Clinic Florida, Weston, Florida

Emory University School of Medicine, Atlanta, Georgia

Alexian Brothers Hospital Network, Elk Grove Village, Illinois

Local Institution - 689, Urbana, Illinois

Northwest Cancer Center, Dyer, Indiana

Norton Cancer Institute - St. Matthews Campus, Louisville, Kentucky

Local Institution - 041, Alexandria, Louisiana

Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana

Local Institution - 027, Baton Rouge, Louisiana

Local Institution - 696, New Orleans, Louisiana

Greater Baltimore Medical Center, Baltimore, Maryland

Center For Cancer And Blood Disorders, Bethesda, Maryland

Maryland Oncology Hematology (Columbia) - USOR, Columbia, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

University of Massachusetts Memorial Medical Center, Worcester, Massachusetts

Minnesota Oncology Hematology, P.A. - Burnsville, Burnsville, Minnesota

Local Institution - 694, Kansas City, Missouri

HCA Midwest Health, Kansas City, Missouri

Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings, Montana

Local Institution - 015, Summit, New Jersey

Local Institution - 042, Bay Shore, New York

Manhattan Hematology Oncology Center, New York, New York

Duke University Hospital, Durham, North Carolina

TriHealth, Good Samaritan Hospital, Cincinnati, Ohio

Local Institution - 644, Cincinnati, Ohio

Local Institution - 037, Cleveland, Ohio

Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio

Ohio Health Corporation, Columbus, Ohio

Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma

Oregon Health and Science University, Portland, Oregon

Local Institution - 048, Hershey, Pennsylvania

Tennessee Oncology, Chattanooga, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Texas Oncology-Austin Midtown, Austin, Texas

Kelsey Seybold Clinic Berthelsen Main Campus, Houston, Texas

Local Institution - 690, Houston, Texas

USOR - Virginia Oncology Associates - Newport News, Newport News, Virginia

Blue Ridge Cancer Care, Roanoke, Virginia

Local Institution - 646, Vancouver, Washington

University Of Wisconsin, Madison, Wisconsin

Local Institution - 080, Ciudad Autanoma De Buenos Aires, Buenos Aires

Local Institution - 083, Villa Elisa, Buenos Aires

Local Institution - 813, Birtinya, Queensland

Local Institution - 812, Douglas, Queensland

Local Institution - 803, Adelaide, South Australia

Local Institution - 806, Bedford Park, South Australia

Local Institution - 802, Clayton, Victoria

Local Institution - 809, East Melbourne, Victoria

Local Institution - 801, Melbourne, Victoria

Local Institution - 811, Murdoch, Western Australia

Local Institution - 807, West Perth, Western Australia

Local Institution - 804, Camperdown, Not set

Local Institution - 800, Fitzroy, Not set

Local Institution - 808, Garran, Not set

Local Institution - 155, Graz, Not set

Local Institution - 154, Linz, Not set

Local Institution - 153, Salzburg, Not set

Local Institution - 156, St Polten, Not set

Local Institution - 150, Vienna, Not set

Local Institution - 151, Wien, Not set

Local Institution - 157, Wien, Not set

Local Institution - 172, Brugge, Not set

Local Institution - 174, Bruxelles, Not set

Local Institution - 056, Curitiba, Parana

Local Institution - 058, Porto Alegre, RIO Grande DO SUL

Local Institution - 050, Porto Alegre, RS

Local Institution - 054, Jau, SAO Paulo

Local Institution - 055, Sao Paulo, SP

Local Institution - 051, Barretos, São Paulo

Local Institution - 053, Rio de Janeiro, Not set

Local Institution - 057, Sao Paulo, Not set

Local Institution - 052, Sao Paulo, Not set

Local Institution - 111, Calgary, Alberta

Local Institution - 103, Edmonton, Alberta

Local Institution - 112, Surrey, British Columbia

Local Institution - 104, Saint John, New Brunswick

Local Institution - 110, St John's, Newfoundland and Labrador

Local Institution - 101, Halifax, Nova Scotia

Local Institution - 109, Ottawa, Quebec

Local Institution - 107, Saskatoon, Saskatchewan

Local Institution - 108, Quebec, Not set

Local Institution - 141, Changsha, Hunan

Local Institution - 129, Nanchang, Jiangxi

Local Institution - 143, Xian, Shaanxi

Local Institution - 142, Shanghai, Shanghai

Local Institution - 145, Taiyuan, Shanxi

Local Institution - 144, Wenzhou, Zhejiang

Local Institution - 140, Beijing, Not set

Local Institution - 139, Beijing, Not set

Local Institution - 138, Beijing, Not set

Local Institution - 126, Changchun, Not set

Local Institution - 121, Chaoyang District, Not set

Local Institution - 135, Guangzhou, Not set

Local Institution - 136, Guangzhou, Not set

Local Institution - 128, Hangzhou City, Not set

Local Institution - 120, Hangzhou, Zhejiang, Not set

Local Institution - 127, Harbin, Not set

Local Institution - 134, Nanjing, Not set

Local Institution - 132, Shanghai, Not set

Local Institution - 130, Shanghai, Not set

Local Institution - 131, Shenyang, Not set

Local Institution - 124, Suzhu, Not set

Local Institution - 133, Tianjin, Not set

Local Institution - 137, Wuhan, Not set

Local Institution - 125, Xian, Not set

Local Institution - 123, Zhengzhou, Not set

Local Institution - 601, Brno, Not set

Local Institution - 600, Ostrava-Poruba, Not set

Local Institution - 602, Prague 2, Not set

Local Institution - 371, Aalborg, Not set

Local Institution - 370, Odense, Not set

Local Institution - 372, Roskilde, Not set

Local Institution - 231, Turku, Varsinais-Suomi

Local Institution - 230, Helsinki, Not set

Local Institution - 232, Oulu, Not set

Local Institution - 463, Argenteuil, Not set

Local Institution - 462, La Roche -Sur-Yon - Cedex 9, Not set

Local Institution - 451, Lille Cedex, Not set

Local Institution - 458, Nancy Cedex, Not set

Local Institution - 454, Nantes, Not set

Local Institution - 452, Paris Cedex, Not set

Local Institution - 456, Paris, Not set

Local Institution - 464, Pessac, Not set

Local Institution - 465, Rouen, Not set

Local Institution - 457, Toulouse Cedex 9, Not set

Local Institution - 308, Kiel, Schleswig-Holstein

Local Institution - 301, Frankfurt am Main, Not set

Local Institution - 300, Hamburg, Not set

Local Institution - 302, Hamburg, Not set

Local Institution - 305, Heidelberg, Not set

Local Institution - 304, Lubeck, Not set

Local Institution - 573, Patras, Achaea

Local Institution - 574, Patra, Achaia

Local Institution - 571, Athens, Not set

Local Institution - 572, Thessaloniki, Not set

Local Institution - 570, Thessaloniki, Not set

Local Institution - 932, Hyderabad, Andhra Pradesh

Local Institution - 930, Bangalore, Karnataka

Local Institution - 934, Ernakulam, Kerala

Local Institution - 933, Mumbai, Maharashtra

Local Institution - 935, Kolkata, West Bengal

Local Institution - 931, Pondicherry, Not set

Local Institution - 752, Cork, Not set

Local Institution - 750, Dublin 9, Not set

Local Institution - 751, Galway, Not set

Local Institution - 874, Afula, HaZafon

Local Institution - 872, Haifa, Not set

Local Institution - 871, Jerusalem, Not set

Local Institution - 870, Tel Aviv, Not set

Local Institution - 873, Tel Hashomer, Not set

Local Institution - 415, Roma, Lazio

Local Institution - 400, Bologna, Not set

Local Institution - 408, Catania, Not set

Local Institution - 414, Genova, Not set

Local Institution - 404, Milano, Not set

Local Institution - 407, Milano, Not set

Local Institution - 410, Novara, Not set

Local Institution - 412, Pavia, Not set

Local Institution - 402, Pisa, Not set

Local Institution - 405, Reggio Calabria, Not set

Local Institution - 413, Reggio Emilia, Not set

Local Institution - 401, Roma, Not set

Local Institution - 403, San Giovanni Rotondo FG, Not set

Local Institution - 409, Terni, Not set

Local Institution - 406, Udine, Not set

Local Institution - 900, Matsuyama, Ehime

Local Institution - 917, Higashi-Ibaraki-gun, Ibaraki

Local Institution - 919, Shimotsuga, Tochigi

Local Institution - 920, Nerima-ku, Tokyo

Local Institution - 918, Shinagawa-ku, Tokyo

Local Institution - 915, Chuo-shi, Yamanashi

Local Institution - 912, Aomori, Not set

Local Institution - 916, Chiba, Not set

Local Institution - 911, Fukuoka, Not set

Local Institution - 903, Kamogawa, Not set

Local Institution - 902, Kyoto-City, Not set

Local Institution - 910, Nagoya, Not set

Local Institution - 901, Nagoya, Not set

Local Institution - 905, Okayama, Not set

Local Institution - 908, Osaka-Sayama, Not set

Local Institution - 907, Osaka, Not set

Local Institution - 913, Sapporo, Not set

Local Institution - 914, Sendai, Not set

Local Institution - 906, Shibuya-ku, Not set

Local Institution - 909, Shinagawa-ku, Tokyo, Not set

Local Institution - 904, Toyohashi, Not set

Local Institution - 974, Daegu, Not set

Local Institution - 973, Gyeonggi-do, Not set

Local Institution - 975, Hwasun-gun, Not set

Local Institution - 971, Seoul, Not set

Local Institution - 976, Seoul, Not set

Local Institution - 972, Seoul, Not set

Local Institution - 970, Seoul, Not set

Local Institution - 977, Seoul, Not set

Local Institution - 182, Mexico City, Distrito Federal

Local Institution - 183, Guadalajara, Jalisco

Local Institution - 181, La Raza, Not set

Local Institution - 180, Mexico City, Not set

Local Institution - 351, Dordrecht, Zuid-Holland

Local Institution - 354, Amsterdam, Not set

Local Institution - 352, Den Haag, Not set

Local Institution - 202, Bergen, Not set

Local Institution - 200, Oslo, Not set

Local Institution - 201, Trondheim, Not set

Local Institution - 631, Bialystok, Podlaskie

Local Institution - 633, Krakow, Not set

Local Institution - 635, Nowy Sacz, Not set

Local Institution - 634, Poznan, Not set

Local Institution - 636, Walbrzych, Not set

Local Institution - 630, Warszawa, Not set

Local Institution - 545, Coimbra, Not set

Local Institution - 543, Lisboa, Not set

Local Institution - 544, Lisboa, Not set

Local Institution - 540, Porto, Not set

Local Institution - 541, Porto, Not set

Local Institution - 791, Pretoria, Gauteng

Local Institution - 790, Cape Town, Western Cape

Local Institution - 792, Kuils River, Western Cape

Local Institution - 514, Pamplona, Navarra

Local Institution - 505, Barcelona, Not set

Local Institution - 502, Barcelona, Not set

Local Institution - 511, Barcelona, Not set

Local Institution - 501, Caceres, Not set

Local Institution - 509, Cordoba, Not set

Local Institution - 510, Madrid, Not set

Local Institution - 516, Madrid, Not set

Local Institution - 504, Madrid, Not set

Local Institution - 513, Madrid, Not set

Local Institution - 503, Malaga, Not set

Local Institution - 508, Murcia, Not set

Local Institution - 506, Oviedo, Not set

Local Institution - 515, Salamanca, Not set

Local Institution - 500, Santiago de Compostela, Not set

Local Institution - 512, Valencia, Not set

Local Institution - 507, Zaragoza, Not set

Local Institution - 272, Boras, Not set

Local Institution - 271, Helsingborg, Not set

Local Institution - 851, Chur, Not set

Local Institution - 850, St. Gallen, Not set

Local Institution - 955, Niao-Sung Hsiang Kaohsiung County, Not set

Local Institution - 952, Taichung City, Not set

Local Institution - 954, Taichung, Not set

Local Institution - 951, Tainan, Taiana, Not set

Local Institution - 956, Taipei, Zhongzheng Dist., Not set

Local Institution - 950, Taipei, Not set

Local Institution - 953, Taoyuan City, Not set

Local Institution - 778, Kavaklıdere, Ankara

Local Institution - 776, Yenimahalle, Ankara

Local Institution - 777, Pendik, Istanbul

Local Institution - 771, Balçova, Izmir

Local Institution - 775, Bornova, Izmir

Local Institution - 773, Samsun, Kurupelit

Local Institution - 770, Ankara, Not set

Local Institution - 772, Gaziantep, Not set

Local Institution - 774, Kayseri, Not set

Local Institution - 702, Nottingham, Nottinghamshire

Local Institution - 705, Belfast Northern Ireland, Not set

Local Institution - 700, Birmingham, Not set

Local Institution - 707, Canterbury Kent, Not set

Local Institution - 704, Lancashire Blackpool, Not set

Local Institution - 701, London, Not set

Local Institution - 709, London, Not set

Local Institution - 706, Oxford, Not set

Local Institution - 711, Portsmouth, Not set

Local Institution - 713, Sutton, Not set

Local Institution - 708, Wolverhampton, Not set

Conditions: Multiple Myeloma

Learn More ›

Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple Myeloma

NCT06041698

Recruiting

This clinical trial evaluates satisfaction and engagement with a text messaging platform (TXT-Chatbot) compared to a patient portal system (MyChart/Patient Portal) for reporting symptoms among patients with multiple myeloma (MM). Multiple myeloma is the third most common hematologic (relating to the blood and blood-forming organs) cancer. Patients with MM typically receive continuous therapy from the time of diagnosis, which often comes with treatment-related toxicities. Symptom burden and healt... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/15/2025

Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

Conditions: Multiple Myeloma

Learn More ›

Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant

NCT05031897

Recruiting

This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however this regimen results in higher rates of TRM than other forms of treatment. In recent years, less intense conditioning regimens with radiation and chemotherapy prior to HSCT have been developed. Radiation... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/14/2025

Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Essential Thrombocythemia, Hodgkin Lymphoma, Myelofibrosis, Myeloid Neoplasm, Non-Hodgkin Lymphoma, Polycythemia Vera, Small Lymphocytic Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphatic System Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome

Learn More ›

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841

Recruiting

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine change in disease symptoms of etentamig compared to standard available therapies in adult participants with relapsed/r... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/13/2025

Locations: University of Alabama at Birmingham - Main /ID# 261434, Birmingham, Alabama +141 locations

University of Alabama at Birmingham - Main /ID# 261434, Birmingham, Alabama

Mayo Clinic Hospital - Phoenix /ID# 263326, Phoenix, Arizona

Alta Bates Summit Medical Center for Research /ID# 261438, Berkeley, California

Providence - St. Jude Medical Center /ID# 262031, Fullerton, California

Cedars-Sinai Medical Center /ID# 261008, Los Angeles, California

Mayo Clinic Hospital Jacksonville /ID# 263324, Jacksonville, Florida

Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 246230, Jacksonville, Florida

Winship Cancer Institute of Emory University /ID# 262525, Atlanta, Georgia

University of Illinois at Chicago /ID# 246349, Chicago, Illinois

Springfield Clinic /ID# 262266, Springfield, Illinois

Center for Cancer and Blood Disorders /ID# 263637, Bethesda, Maryland

Dana-Farber Cancer Institute /ID# 261554, Boston, Massachusetts

Regents of the University of Michigan /ID# 261577, Ann Arbor, Michigan

Karmanos Cancer Institute - Detroit /ID# 266298, Detroit, Michigan

Henry Ford Hospital /ID# 262704, Detroit, Michigan

Barbara Ann Karmanos Cancer Institute - McLaren Greater Lansing /ID# 259891, Lansing, Michigan

Mayo Clinic - Rochester /ID# 246228, Rochester, Minnesota

University of Missouri Hospital /ID# 261553, Columbia, Missouri

New York Cancer & Blood Specialists - Bay Shore /ID# 261524, Bay Shore, New York

Eastchester Center for Cancer Care /ID# 262952, Bronx, New York

New York Cancer & Blood Specialists - Lake Success Medical Oncology /ID# 262953, New Hyde Park, New York

New York Cancer and Blood Specialists - New York /ID# 262951, New York, New York

University of North Carolina /ID# 259854, Chapel Hill, North Carolina

Levine Cancer Institute /ID# 246199, Charlotte, North Carolina

Duke University Medical Center /ID# 259694, Durham, North Carolina

University Of Cincinnati Medical Center /ID# 246415, Cincinnati, Ohio

Cleveland Clinic Main Campus /ID# 246183, Cleveland, Ohio

Medical University of South Carolina /ID# 259692, Charleston, South Carolina

Baptist Memorial Hospital /ID# 270910, Memphis, Tennessee

The West Clinic /ID# 262444, Memphis, Tennessee

Virginia Cancer Specialists - Fairfax /ID# 262792, Fairfax, Virginia

VCU Massey Cancer Center: Dalton Oncology Clinic /ID# 261944, Richmond, Virginia

St George Hospital /ID# 261806, Kogarah, New South Wales

Liverpool Hospital /ID# 262159, Liverpool, New South Wales

Calvary Mater Newcastle /ID# 261804, Waratah, New South Wales

Princess Alexandra Hospital /ID# 261810, Woolloongabba, Queensland

Monash Health - Monash Medical Centre /ID# 262158, Clayton, Victoria

St Vincent's Hospital Melbourne /ID# 261808, Fitzroy Melbourne, Victoria

Box Hill Hospital /ID# 262784, Melbourne, Victoria

Universitaetsklinikum Krems /ID# 261509, Krems an der Donau, Niederoesterreich

Ordensklinikum Linz GmbH Elisabethinen /ID# 245609, Linz, Oberoesterreich

Medizinische Universitaet Graz /ID# 261908, Graz, Steiermark

Klinik Ottakring /ID# 245829, Vienna, Wien

Algemeen Ziekenhuis klina /ID# 260856, Brasschaat, Antwerpen

AZ Sint-Jan Brugge /ID# 245345, Brugge, Not set

University Health Network_Princess Margaret Cancer Centre /ID# 261566, Toronto, Ontario

Beijing Chaoyang Hospital,Capital Medical University /ID# 245533, Beijing, Beijing

Peking Union Medical College Hospital (East) - Dongdan Campus /ID# 245545, Beijing, Beijing

Fujian Medical University Union Hospital /ID# 245558, Fuzhou, Fujian

Sun Yat-Sen University Cancer Center /ID# 245542, Guangzhou, Guangdong

People's Hospital of Henan Province /ID# 260918, Zhengzhou, Henan

Henan Cancer Hospital /ID# 245536, Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 245549, Wuhan, Hubei

Zhongda Hospital Southeast University /ID# 245563, Nanjing, Jiangsu

The First Affiliated Hospital of Soochow University /ID# 245544, Suzhou, Jiangsu

The First Affiliated Hospital of Nanchang University /ID# 245537, Nanchang, Jiangxi

The First Hospital of China Medical University /ID# 245547, Shenyang, Liaoning

Shanghai Tongji Hospital /ID# 245539, Shanghai, Shanghai

Institute of Hematology and Blood Diseases Hospital /ID# 265702, Tianjin, Tianjin

Tianjin Medical University General Hospital /ID# 260851, Tianjin, Tianjin

The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 260883, Hangzhou, Zhejiang

Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 260882, Hangzhou, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University /ID# 245550, Wenzhou, Zhejiang

Fakultní Nemocnice Brno - Jihlavská /ID# 245689, Brno, Brno-mesto

Fakultní nemocnice Hradec Králové - Sokolská /ID# 245690, Hradec Králové, Hradec Kralove

Fakultni Nemocnice Ostrava /ID# 245686, Ostrava, Ostrava-mesto

Vseobecna fakultni nemocnice v Praze /ID# 245691, Praha, Not set

Odense University Hospital /ID# 260924, Odense, Syddanmark

Sygehus Lillebalt, Vejle /ID# 260923, Vejle, Syddanmark

Ch Saint Quentin /Id# 261856, St Quentin CEDEX, Aisne

Centre Hospitalier du Mans /ID# 261852, Le Mans CEDEX 9, Sarthe

CH Henri Duffaut /ID# 261844, Avignon CEDEX 9, Vaucluse

Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 261854, Orléans, Not set

Universitaetsklinikum Freiburg /ID# 262147, Freiburg, Baden-Wuerttemberg

Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 260689, Berlin, Not set

Universitaetsklinikum Hamburg-Eppendorf /ID# 260651, Hamburg, Not set

Alexandra General Hospital /ID# 240591, Athens, Attiki

University General Hospital Attikon /ID# 240592, Athens, Attiki

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 240596, Athens, Not set

General University Hospital of Thessaloniki AXEPA /ID# 240595, Thessaloniki, Not set

Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz /ID# 261648, Gyor, Gyor-Moson-Sopron

Semmelweis Egyetem /ID# 261647, Budapest, Not set

Del-pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet /ID# 261646, Budapest, Not set

The Chaim Sheba Medical Center /ID# 245497, Ramat Gan, Tel-Aviv

Tel Aviv Sourasky Medical Center /ID# 245495, Tel Aviv, Tel-Aviv

Shaare Zedek Medical Center /ID# 245681, Jerusalem, Yerushalayim

Rabin Medical Center /ID# 245498, Petah Tikva, Not set

ASST Ovest Milanese /ID# 256813, Legnano, Milano

A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 256808, Torino, Piemonte

Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 256810, Rome, Roma

Azienda Ospedaliero Universitaria delle Marche /ID# 256812, Ancona, Not set

AOU Policlinico G. Rodolico - San Marco /ID# 256814, Catania, Not set

Anjo Kosei Hospital /ID# 263434, Anjo, Aichi

Nagoya City University Hospital /ID# 263320, Nagoya, Aichi

Chiba University Hospital /ID# 262006, Chiba-shi, Chiba

University of Fukui Hospital /ID# 264222, Yoshida-gun, Fukui

Kyushu University Hospital /ID# 264704, Fukuoka-shi, Fukuoka

Gifu Municipal Hospital /ID# 263321, Gifu-shi, Gifu

Gunma University Hospital /ID# 262580, Maebashi-shi, Gunma

Chugoku Central Hospital /ID# 263431, Fukuyama, Hiroshima

Hyogo Prefectural Amagasaki General Medical Center /ID# 265696, Amagasaki, Hyogo

University Hospital Kyoto Prefectural University of Medicine /ID# 262585, Kyoto-shi, Kyoto

Miyagi Cancer Center /ID# 265094, Natori, Miyagi

Naha City Hospital /ID# 263972, Naha, Okinawa

The University of Osaka Hospital /ID# 263974, Suita-shi, Osaka

Saitama Cancer Center /ID# 262586, Kitaadachi-gun, Saitama

Japanese Red Cross Medical Center /ID# 261717, Shibuya-ku, Tokyo

Seoul National University Hospital /ID# 245491, Seoul, Seoul Teugbyeolsi

Samsung Medical Center /ID# 245492, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St. Marys Hospital /ID# 245493, Seoul, Seoul Teugbyeolsi

Ulsan University Hospital /ID# 245490, Ulsan, Ulsan Gwang Yeogsi

Yonsei University Health System Severance Hospital /ID# 245489, Seoul, Not set

Uniwersytecki Szpital Kliniczny We Wrocławiu /ID# 260172, Wroclaw, Dolnoslaskie

Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie /ID# 260168, Lublin, Lubelskie

Uniwersyteckie Centrum Kliniczne /ID# 260169, Gdansk, Pomorskie

Fundacao Champalimaud /ID# 246258, Lisbon, Lisboa

Unidade Local de Saude de Santa Maria, EPE /ID# 246255, Lisboa, Not set

Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE /ID# 246257, Porto, Not set

Alberts Cellular Therapy /ID# 245725, Pretoria, Gauteng

Constantiaberg Haematology /ID# 261320, Cape Town, Western Cape

Haemalife Inc. /ID# 245724, Kuilsrivier, Western Cape

Instituto Catalan de Oncologia (ICO) Badalona /ID# 246398, Badalona, Barcelona

Complejo Hospitalario Universitario Ourense /ID# 246400, Orense, Ourense

Hospital de Leon /ID# 261624, Leon, Not set

Hospital General Universitario Gregorio Maranon /ID# 246401, Madrid, Not set

Hospital Universitario de Salamanca /ID# 262218, Salamanca, Not set

Hospital Universitario y Politecnico La Fe /ID# 261625, Valencia, Not set

Helsingborgs Lasarett /ID# 262513, Helsingborg, Skane Lan

Uddevalla sjukhus /ID# 262034, Uddevalla, Vastra Gotalands Lan

Falu Lasarett /ID# 262231, Falun, Not set

National Taiwan University Hospital /ID# 245482, Taipei City, Taipei

China Medical University Hospital /ID# 245483, Taichung, Not set

Taichung Veterans General Hospital /ID# 261142, Taichung, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 261672, Ankara, Not set

Antalya Egitim Ve Arastirma Hastanesi /ID# 261674, Antalya, Not set

Trakya University Medical Facu /ID# 261673, Edirne, Istanbul, Not set

Istanbul Florence Nightingale Hospital /ID# 271543, Şişli, Not set

Addenbrooke's Hospital /ID# 261104, Cambridge, Cambridgeshire

Guys and St Thomas NHS Foundation Trust /ID# 262488, London, Greater London

Nottingham City Hospital /ID# 261105, Nottingham, Nottinghamshire

NHS Lothian /ID# 261106, Edinburgh, Not set

The Christie Hospital /ID# 261102, Manchester, Not set

Conditions: Multiple Myeloma

Learn More ›

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

NCT05145400

Recruiting

This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/09/2025

Locations: University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina +4 locations

Conditions: Multiple Myeloma, Cancer

Learn More ›